Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

Video content above is prompted by the following:

Iopofosine I 131 in Previously Treated WM

Study Overview:
The phase 2 CLOVER-WaM trial evaluated the efficacy and safety of iopofosine I 131, a targeted radiopharmaceutical, in patients with previously treated WM. This international, multicenter, open-label study (ASH 2024, abstract #861) demonstrated promising clinical activity in a population with limited treatment options.

Key Findings:

• Efficacy: Iopofosine I 131 showed meaningful response rates, suggesting a potential role in relapsed or refractory WM.
• Safety Profile: The treatment was generally well tolerated, with manageable adverse events, supporting its feasibility for integration into clinical practice.

Potential Impact on WM Treatment Paradigm:
The introduction of iopofosine I 131 could expand therapeutic options for WM, particularly for patients with resistance or intolerance to standard therapies. As a novel radiopharmaceutical, it introduces a targeted radiation-based approach, complementing existing chemotherapy, Bruton tyrosine kinase inhibitors, and monoclonal antibodies.

Future Research Implications:

• Combination Strategies: Exploring synergies between iopofosine I 131 and current WM therapies
• Earlier-Line Integration: Investigating its role in earlier treatment settings to improve long-term outcomes
• Biomarker Identification: Defining patient subgroups most likely to benefit from radiopharmaceutical therapy
• Comparative Studies: Evaluating its effectiveness vs existing standard-of-care options

The results from CLOVER-WaM highlight iopofosine I 131 as a promising addition to the WM treatment landscape, warranting further investigation in future clinical trials.